Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04713982 · ClinicalTrials.gov registry record · Phase 2
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
A Phase 2 study of Huntington Disease, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04713982 is a Phase 2 study of Huntington Disease that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 30 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04713982, a Phase 2 study of Huntington Disease, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Examine the effects of deutetrabenazine on functional speech and gait impairment
Conditions Studied
Interventions
- DRUG Deutetrabenazine
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04713982
The ClinicalTrials.gov registry entry for NCT04713982 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (95% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Deutetrabenazine is the first listed.
NCT04713982 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT04713982 about?
NCT04713982 is a clinical study titled "Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease". Examine the effects of deutetrabenazine on functional speech and gait impairment
What is the current status of trial NCT04713982?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-11-19. Estimated completion is 2026-10-01.
What conditions does trial NCT04713982 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT04713982?
The interventions under investigation include: Deutetrabenazine (DRUG).
Who is sponsoring clinical trial NCT04713982?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04713982 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Creatine Safety and Tolerability in Premanifest HD: PRECREST
COMPLETED · Phase 2
-
Atomoxetine and Huntington's Disease
COMPLETED · Phase 2
-
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
COMPLETED · Phase 2
-
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.